Louvain-La-Neuve, Belgium, June 30, 2026 –IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today the entering into effect of a contract with Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), for the installation of two Proteus®ONE[1] compact proton therapy solutions at the IPO-Porto facilities in Porto, Portugal. The two Proteus®ONE systems will be the first proton therapy systems in the country and will serve as the National Proton Therapy Center of Portugal.
Signed last April, the contract enters into effect after a statutory thorough review of the selection process by the Portuguese Tribunal de Contas (Court of Auditors). The contract between IPO-Porto and IBA also includes a period of operation and maintenance services provided by IBA.
This contract comes after a public tender published in November of 2025, that was awarded to IBA. This public tender was launched after an agreement between the Amancio Ortega Gaona Foundation (FAO), the Portuguese Ministry of Health, the Portuguese Ministry of Territorial Cohesion and IPO-Porto.
Ad Statistics
Times Displayed: 16578
Times Visited: 46 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
The two compact proton therapy solutions will be installed side by side in a configuration designed to maximize clinical availability, operational flexibility, and patient treatment efficiency. As the market-leading compact proton therapy solution, Proteus®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities.
IPO-Porto expects to start treating patients with this cutting-edge technology in 2029.
Olivier Legrain, Chief Executive Officer of IBA, commented: “In line with our mission and strategy to make innovative proton therapy solutions accessible to more patients who can benefit from that modality of cancer treatment, we are proud to have been selected to install the first proton therapy center in Portugal. We look forward to working with IPO-Porto, renowned for its expertise in oncology, to establish the country’s most advanced cancer care center, powered by our cutting-edge technology.”
Dr. Julio Oliveira, Chairman of the Board of Directors of IPO-Porto, said: “The awarding of this equipment is the moment the National Proton Therapy Centre becomes irreversible. For years, we worked toward a single goal: that Portugal could finally offer its patients — including children — the high-precision treatment that today forces them abroad. That future now has a date. This is also public proof of an exceptional partnership. The Amancio Ortega Foundation and the Portuguese Government believed in this project when it was still just an ambition. It is because of that trust that we are here today.”
The typical end-user price for one Proteus®ONE solution, including a multi-year maintenance contract, ranges between € 35 and 45 million.
